CN118436644A - Application of Fuziling in preparing medicament for treating ulcerative colitis - Google Patents
Application of Fuziling in preparing medicament for treating ulcerative colitis Download PDFInfo
- Publication number
- CN118436644A CN118436644A CN202410471994.9A CN202410471994A CN118436644A CN 118436644 A CN118436644 A CN 118436644A CN 202410471994 A CN202410471994 A CN 202410471994A CN 118436644 A CN118436644 A CN 118436644A
- Authority
- CN
- China
- Prior art keywords
- ulcerative colitis
- treating
- medicament
- use according
- treating ulcerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 47
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 3
- FPECZWKKKKZPPP-JIHBGUTISA-N 80665-72-1 Chemical compound O[C@@H]1[C@H]2[C@@H]3C4([C@@H]5[C@H]6OC)[C@@H](O)CC[C@@]5(COC)CN(CC)C4C6[C@@]2(O)[C@@H](O)[C@H](OC)C1C3 FPECZWKKKKZPPP-JIHBGUTISA-N 0.000 claims description 3
- 239000004012 Tofacitinib Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 3
- 229960001350 tofacitinib Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 241000173529 Aconitum napellus Species 0.000 abstract description 18
- 229940023019 aconite Drugs 0.000 abstract description 18
- 210000001072 colon Anatomy 0.000 abstract description 17
- 238000004904 shortening Methods 0.000 abstract description 9
- 230000004580 weight loss Effects 0.000 abstract description 9
- 230000001575 pathological effect Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 206010009887 colitis Diseases 0.000 abstract description 4
- 239000000178 monomer Substances 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 24
- 229940079593 drug Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229920003045 dextran sodium sulfate Polymers 0.000 description 6
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 5
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 5
- 229940039750 aconitine Drugs 0.000 description 5
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- -1 alkaloid compounds Chemical class 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an application of aconite root in preparing a medicament for treating ulcerative colitis, and relates to the field of biological medicine. The aconite root medicine can improve ulcerative colitis symptoms, reduce weight loss, inhibit colon shortening and reduce pathological scores, is hopeful to become a new inflammatory bowel disease treatment medicine, is used for treating ulcerative colitis, and provides reference for developing active ingredients of traditional Chinese medicine monomers for treating colitis.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to an application of aconite root in preparing a medicament for treating ulcerative colitis.
Background
Ulcerative colitis is a kind of inflammatory bowel disease, the pathogenesis of which is unknown so far, and has the characteristics of persistent difficult recovery, early onset, long course of disease, fatal serious complications and the like, and the prevalence rises year by year. At present, the drugs for treating ulcerative colitis clinically are mainly: 5-aminosalicylic acid medicines, glucocorticoid medicines, thiopurine medicines and biological preparation medicines have the defects of multiple adverse reactions, high price, easy generation of tolerance and the like.
The traditional Chinese medicine decoction has the characteristics of less adverse reaction, low medical cost, obvious curative effect and the like, is widely applied clinically, and a plurality of great progress in the research and development of new medicines since the past are also based on the development of natural products, such as salicylic acid and artemisinin. Therefore, a medicine capable of treating ulcerative colitis is sought from the perspective of traditional Chinese medicine, and a new treatment strategy can be provided for the disease.
Disclosure of Invention
Aiming at the problems, the invention provides the application of the aconite in preparing the medicine for treating the ulcerative colitis, which can improve the symptoms of the ulcerative colitis, reduce weight loss, inhibit colon shortening and reduce pathological scores, so that the aconite is hopeful to become a new medicine for treating inflammatory bowel disease, is used for treating the ulcerative colitis and provides reference for developing active ingredients of traditional Chinese medicine monomers for treating the colitis.
The invention provides an application of aconite root in preparing a medicament for treating ulcerative colitis, which has the following structural formula:
The inventor finds that aconite mainly contains alkaloid compounds in the research process, wherein a plurality of toxic fat-soluble alkaloids volatilize along with the decoction process, and aconitine is water-soluble alkaloid with higher content in aconite, and the medicine has higher safety and lower price in vivo and in vitro experiments, can better improve the symptoms of ulcerative colitis mice at lower dosage (15 mg/kg), can improve the weight loss, colon shortening, hematochezia, colon structural damage and pathological score increase of the ulcerative colitis mice, has low medicine toxicity and high water solubility, and is hopeful to become an ulcerative colitis treatment medicine for treating the ulcerative colitis. The aconite root extract can improve ulcerative colitis symptoms, reduce weight loss, inhibit colon shortening and reduce pathological score, and provides reference for developing active ingredients of traditional Chinese medicine monomers for treating colitis.
In one embodiment, the medicament for treating ulcerative colitis further comprises a pharmaceutically acceptable adjuvant.
In one embodiment, the adjuvant comprises at least 1 of a solvent, a disintegrant, a flavoring agent, a colorant, a lubricant, an antioxidant, a preservative, a binder, a filler, or a thickener.
In one embodiment, the fuziline is administered at a dose of 12-48 mg/kg body weight.
In one embodiment, the fuziline is administered at a dose of 12-18 mg/kg body weight.
In one embodiment, the dosage form of the medicament for treating ulcerative colitis comprises capsules, granules, tablets, injections, oral liquids, pills, pastes, sustained release agents, controlled release agents or dispersible tablets.
In one embodiment, the method of administering the medicament for treating ulcerative colitis comprises: oral, sublingual, intravenous or transdermal administration.
In one embodiment, the ulcerative colitis is a clinical indication of aminosalicylic acid, tofacitinib, glucocorticoids and/or immunomodulators.
The ulcerative colitis is ulcerative colitis treatable with aminosalicylic acid, tofacitinib, glucocorticoids and/or immunomodulators, i.e. belongs to one of the clinical indications of the above drugs.
Experiments prove that the aconite root medicine has direct and obvious inhibition effect on the ulcerative colitis induced by the DSS; so that the medicine can be used as a medicine for treating ulcerative colitis and can be used for treating diseases by the existing medicine for treating ulcerative colitis.
Compared with the prior art, the invention has the following beneficial effects:
the aconite can improve ulcerative colitis symptoms, reduce weight loss, inhibit colon shortening and reduce pathological scores, so that the aconite is expected to become a new inflammatory bowel disease treatment drug, is used for treating ulcerative colitis, and provides reference for developing active ingredients of traditional Chinese medicine monomers for treating colitis.
Drawings
FIG. 1 is a graph showing the results of the effect of aconite in the example on the alleviation of weight loss in ulcerative colitis mice;
FIG. 2 is a graph showing the results of improving the colonic shortening effect of the aconite ulcerative colitis mice in the example, wherein the graph is a schematic diagram of the colon length of the mice and a data statistical result graph from left to right;
FIG. 3 is a graph showing the results of the reduction of pathological scoring by aconite in the ulcerative colitis mice in the example, wherein the left graph shows the results of the scoring by the disease activity index in mice, and the right graph shows the results of the scoring by the colon index in mice;
FIG. 4 is a graph showing the results of the protective effect of aconite in the example on colon structure of ulcerative colitis mice.
Detailed Description
In order that the invention may be readily understood, a more complete description of the invention will be rendered by reference to the appended drawings. Preferred embodiments of the present invention are shown in the drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The source is as follows:
The reagents, materials and equipment used in the examples are all commercially available sources unless otherwise specified; the test methods are conventional in the art unless otherwise specified.
Examples
1. Fuziling has effect in relieving weight loss of ulcerative colitis mice.
Ulcerative colitis model with 3% Dextran Sodium Sulfate (DSS) free water: 32C 57BL/6 mice with the age of 8-12 weeks are randomly divided into 4 groups after being adaptively bred for one week, and 6 mice in each group: a. control group: drinking double distilled water, and performing gastric lavage to administer 200uL of physiological saline for injection; dss group: 200uL of physiological saline for injection is administrated by gavage after drinking 3% DSS; dss+aconite group: drinking 3% DSS, and administering radix Aconiti lateralis Preparata solution according to 15mg/kg of mice weight by intragastric administration; dss+positive drug control: 5-aminosalicylic acid at 75mk/kg was administered by gavage with 3% DSS. The stomach is irrigated once a day. In this example, aconitine was purchased from Chengomant Biotechnology Co.
The control group was removed, 3% dss was freely drunk for the first 7 days of the remaining three groups, double distilled water was used instead on day 8, and after blood and feces were collected on day 11, mice were sacrificed and the colon was collected.
Experimental results show that aconite can relieve the weight loss of ulcerative colitis mice, as shown in figure 1.
2. Fuziling has effect in improving colonic shortening of ulcerative colitis mice.
The modeling of mice was performed as described in step one of the present examples, and data statistics were performed after the measurement of colon length of mice.
Experimental results show that aconitine has an improving effect on colon shortening of ulcerative colitis mice, as shown in figure 2.
3. Fuziling has effect of reducing pathological score of ulcerative colitis mice.
Mice were observed and scored for weight loss, colon shortening, intestinal mucosa destruction, etc., as described in step one of this example.
Experimental results show that aconitine has a reducing effect on pathological scores of ulcerative colitis mice, as shown in figure 3.
4. Fuziling has protective effect on colon structure of ulcerative colitis mice.
Mouse modeling mode as described in step one of this example, the colon of the mouse was HE stained and the colon of the mouse was scored based on crypt destruction, mucosal defect, inflammation, lesion extent, etc. of the mouse by observing the HE staining results.
Experimental results show that aconitine has protective effect on colon structure of ulcerative colitis mice, as shown in figure 4.
The technical features of the above-described embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above-described embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The above examples illustrate only a few embodiments of the invention, which are described in detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (7)
1. An application of Fuziling in preparing a medicament for treating ulcerative colitis, wherein the Fuziling has the following structural formula:
2. The use according to claim 1, wherein the medicament for treating ulcerative colitis further comprises a pharmaceutically acceptable adjuvant.
3. The use according to claim 2, wherein the auxiliary material comprises at least 1 of a solvent, a disintegrant, a flavoring agent, a coloring agent, a lubricant, an antioxidant, a preservative, a binder, a filler, or a thickener.
4. The use according to claim 1, wherein the fuziline is administered at a dose of 12-48 mg/kg body weight.
5. The use according to any one of claims 1 to 4, wherein the dosage form of the medicament for treating ulcerative colitis comprises a capsule, a granule, a tablet, an injection, an oral liquid, a pill, a paste, a sustained release agent, a controlled release agent or a dispersible tablet.
6. The use according to claim 5, wherein the route of administration of the medicament for treating ulcerative colitis comprises: oral, sublingual, intravenous or transdermal administration.
7. The use according to claim 1, wherein the ulcerative colitis is a clinical indication of aminosalicylic acid, tofacitinib, glucocorticoids and/or immunomodulators.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410471994.9A CN118436644A (en) | 2024-04-19 | 2024-04-19 | Application of Fuziling in preparing medicament for treating ulcerative colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410471994.9A CN118436644A (en) | 2024-04-19 | 2024-04-19 | Application of Fuziling in preparing medicament for treating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118436644A true CN118436644A (en) | 2024-08-06 |
Family
ID=92318697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410471994.9A Pending CN118436644A (en) | 2024-04-19 | 2024-04-19 | Application of Fuziling in preparing medicament for treating ulcerative colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118436644A (en) |
-
2024
- 2024-04-19 CN CN202410471994.9A patent/CN118436644A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014305430B2 (en) | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
| CN112426461B (en) | Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof | |
| WO2019134159A1 (en) | Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor | |
| CN118436644A (en) | Application of Fuziling in preparing medicament for treating ulcerative colitis | |
| CN111686202A (en) | Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof | |
| CN101069688A (en) | Medicine composition containing theocin-like medicines and vitamin K | |
| US20240366550A1 (en) | Drug for Treating Prostatitis or Benign Prostatic Hyperplasia (BPH) | |
| CN116077512A (en) | Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin | |
| CN106619697A (en) | Drug for treating cirrhosis with ascites, preparation method thereof and application | |
| CN111920835A (en) | Application of medicinal preparation in preparing medicament for treating senile dementia | |
| CN114272254B (en) | Application of combination of glycyrrhetinic acid and paeoniflorin in treating liver injury and liver fibrosis | |
| CN118436667A (en) | Application of sophoricoside in preparation of medicine for treating ulcerative colitis | |
| CN109700757A (en) | A kind of Mesalazine and the compound preparation of paracetamol and application thereof | |
| WO2022183493A1 (en) | Application of polyphenol compound | |
| CN115624543B (en) | Medicine for treating migraine, pharmaceutical composition, preparation method and pharmaceutical application thereof | |
| CN114159435B (en) | Application of Fuziling in preparing medicine for treating arthritis | |
| CN115105514B (en) | Pharmaceutical composition for protecting gastric mucosa and treating gastric ulcer as well as preparation method and application thereof | |
| WO2003090749A1 (en) | Use of berberine with high solubility in preparation of medicament | |
| CN109432082B (en) | Pharmaceutical composition for preventing and treating chemical liver injury | |
| CN110721310B (en) | Application of pharmaceutical composition in preparation of medicine for treating acute hemorrhagic brain injury | |
| CN118178365A (en) | Application of dendrobinol and composition thereof in preparation of medicines or functional foods for preventing and/or treating digestive tract inflammation | |
| CN109125427B (en) | Penyanjing suppository and preparation method thereof | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| US20210205392A1 (en) | Anisomeles indica extract composition for Treating or Improving Gastric Ulcer | |
| CN116036102A (en) | Use of Manacastine to reduce intestinal damage caused by XELOX combination treatment regimen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |